Edesa Biotech Appoints Weiler as CFO, Succeeding Lemieux

Dow Jones
04-05
 

By Connor Hart

 

Edesa Biotech named Peter Weiler as its finance chief, succeeding Stephen Lemieux, effective May 1.

Weiler, 56, has experience in finance and corporate strategy with both the biotechnology and pharmaceutical industries, the Toronto-based company said Friday.

He most recently was president of Exzell Pharma, a privately held, commercial-stage pharmaceutical company. Prior, he held executive posts at companies including Biosyent and Cipher Pharmaceuticals, as well as research and financial positions at Eli Lilly Canada.

Weiler will receive an annual base salary of $300,000. He will additionally be eligible for a target annual bonus valued at 40% of his base salary, as well as other benefits, according to a filing with the Securities and Exchange Commission.

Weiler succeeds Lemieux, who is stepping down as CFO to pursue other professional opportunities. He will continue to provide financial advisory services to Edesa on a contract basis following the planned transition, the company said.

 

Write to Connor Hart at connor.hart@wsj.com

 

(END) Dow Jones Newswires

April 04, 2025 16:41 ET (20:41 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10